Published in Int J Neuropsychopharmacol on December 01, 2004
Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia. J Cent Nerv Syst Dis (2011) 1.15
Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) (2006) 0.95
Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats. Pharm Res (2012) 0.92
Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genet Med (2008) 0.92
Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology (Berl) (2005) 0.91
Inhibition of human MDR1 and BCRP transporter ATPase activity by organochlorine and pyrethroid insecticides. J Biochem Mol Toxicol (2012) 0.84
Comparative Pharmacology of Risperidone and Paliperidone. Drugs R D (2015) 0.84
New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther (2010) 0.83
Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein. Biol Pharm Bull (2008) 0.82
Neuroprotection of paliperidone on SH-SY5Y cells against β-amyloid peptide(25-35), N-methyl-4-phenylpyridinium ion, and hydrogen peroxide-induced cell death. Psychopharmacology (Berl) (2011) 0.81
Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10/*10. Br J Pharmacol (2011) 0.79
Association of common genetic variants with risperidone adverse events in a Spanish schizophrenic population. Pharmacogenomics J (2012) 0.79
Enhanced brain disposition and effects of Δ9-tetrahydrocannabinol in P-glycoprotein and breast cancer resistance protein knockout mice. PLoS One (2012) 0.78
ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. PeerJ (2016) 0.78
An in vitro evaluation of guanfacine as a substrate for P-glycoprotein. Neuropsychiatr Dis Treat (2011) 0.76
Regulation of P-glycoprotein expression in brain capillaries in Huntington's disease and its impact on brain availability of antipsychotic agents risperidone and paliperidone. J Cereb Blood Flow Metab (2015) 0.75
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy. Biomed Res Int (2015) 0.75
CYP2D6 polymorphisms and their influence on risperidone treatment. Pharmgenomics Pers Med (2016) 0.75
The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions. Neuropsychopharmacology (2017) 0.75
Serum Concentrations of Paliperidone after Administration of the Long-Acting Injectable Formulation. Ther Drug Monit (2017) 0.75
Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA (2003) 1.93
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet (2008) 1.50
Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry (2007) 1.38
Methodological challenges of characterizing usual care psychotherapeutic practice. Adm Policy Ment Health (2009) 1.33
How should we assess the effects of exposure to dietary polyphenols in vitro? Am J Clin Nutr (2004) 1.33
Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radic Res (2004) 1.31
Cocoa and health: a decade of research. Br J Nutr (2007) 1.30
Pharmacist-conducted medication reconciliation in an emergency department. Am J Health Syst Pharm (2007) 1.28
Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos (2003) 1.22
Metabolism of dietary procyanidins in rats. Free Radic Biol Med (2003) 1.22
Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther (2012) 1.16
Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol (2002) 1.15
Modafinil and cocaine interactions. Am J Drug Alcohol Abuse (2006) 1.14
In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci (2002) 1.11
A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol (2006) 1.10
Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol (2009) 1.08
Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos (2008) 1.07
Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos (2009) 1.06
Short-term administration of (-)-epigallocatechin gallate reduces hepatic steatosis and protects against warm hepatic ischemia/reperfusion injury in steatotic mice. Liver Transpl (2005) 1.04
Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl) (2004) 1.04
Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy (2004) 1.04
Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients. Clin Ther (2007) 1.01
New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin Drug Deliv (2005) 0.99
Microbial aromatic acid metabolites formed in the gut account for a major fraction of the polyphenols excreted in urine of rats fed red wine polyphenols. J Nutr (2003) 0.99
Placental passage of tricyclic antidepressants. Biol Psychiatry (2005) 0.99
Adverse drug events after hospital discharge in older adults: types, severity, and involvement of Beers Criteria Medications. J Am Geriatr Soc (2013) 0.97
Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology (2004) 0.97
Rapid reversed phase ultra-performance liquid chromatography analysis of the major cocoa polyphenols and inter-relationships of their concentrations in chocolate. J Agric Food Chem (2007) 0.95
Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) (2006) 0.95
Development and pilot testing of guidelines to monitor high-risk medications in the ambulatory setting. Am J Manag Care (2010) 0.94
Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana. J Pharmacol Exp Ther (2006) 0.94
Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology (2006) 0.94
Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol (2003) 0.94
Heparin-induced thrombocytopenia in the pediatric population: a review of current literature. J Pediatr Pharmacol Ther (2012) 0.93
Clinical pharmacokinetics of sertraline. Clin Pharmacokinet (2002) 0.93
Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther (2003) 0.93
Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet (2003) 0.92
Green tea (Camellia sinensis) extract does not alter cytochrome p450 3A4 or 2D6 activity in healthy volunteers. Drug Metab Dispos (2004) 0.92
Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic. J Thromb Thrombolysis (2010) 0.92
An effective indoor mesocosm for studying populations of Anopheles gambiae in temperate climates. J Am Mosq Control Assoc (2009) 0.92
Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology (Berl) (2005) 0.91
Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions. Toxicology (2010) 0.91
Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers. Clin Pharmacokinet (2005) 0.90
Randomized trial of a warfarin communication protocol for nursing homes: an SBAR-based approach. Am J Med (2011) 0.89
Plant SET- and RING-associated domain proteins in heterochromatinization. Plant J (2007) 0.89
Antidepressants in amniotic fluid: another route of fetal exposure. Am J Psychiatry (2006) 0.89
Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos (2004) 0.88
The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine. Drug Metab Dispos (2006) 0.87
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J (2009) 0.87
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Ann Pharmacother (2012) 0.87
Milk decreases urinary excretion but not plasma pharmacokinetics of cocoa flavan-3-ol metabolites in humans. Am J Clin Nutr (2009) 0.87
The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. Drug Metab Rev (2007) 0.87
Enantiospecific determination of DL-methylphenidate and DL-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.86
Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate. J Am Acad Child Adolesc Psychiatry (2007) 0.86
An electronic health record-based intervention to increase follow-up office visits and decrease rehospitalization in older adults. J Am Geriatr Soc (2014) 0.85
An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study. Drug Metab Dispos (2013) 0.85
The need for PGY2-trained clinical pharmacy specialists. Pharmacotherapy (2014) 0.85
Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem (2010) 0.84
Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos (2003) 0.84
Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine. J Clin Pharmacol (2002) 0.84
Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers. J Clin Psychopharmacol (2004) 0.84
Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. Clin Ther (2013) 0.84
Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol (2006) 0.83
Agave (Agave americana): an evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother (2006) 0.83
Aripiprazole brain concentration is altered in P-glycoprotein deficient mice. Schizophr Res (2009) 0.83